Appeals court upholds ruling in patent suit between Glaxo, Biogen

theflyonthewall.com

Biogen Idec (BIIB) and Roche's (RHHBY) Genentech unit appealed a district court’s construction of a disputed claim term, “anti-CD20 antibody,” that narrowed the term in their patent dispute with GlaxoSmithKline (GSK). An appeals court concluded that "the district court did not err in finding a clear and unmistakable disclaimer" and affirmed the lower court's decision.

View Comments (0)